Solid Biosciences Reports Positive Initial Clinical Data from Next ...
Feb 18, 2025 · INSPIRE DUCHENNE is a first-in-human, open-label, single-dose, multicenter Phase 1/2 clinical trial to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric participants with a genetically confirmed Duchenne diagnosis with a …
Solid Biosciences Reports Inducement Grants Under Nasdaq …
Feb 4, 2025 · Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy ...
© 2020 Solid Biosciences 15. SGT-001 Clinical Biomarker Results Support Continued Development • Interim results following SGT- 001 administration show dose - dependent, …
Solid Biosciences Announces Pricing of Underwritten Offering
Feb 18, 2025 · Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy ...
Solid Biosciences Receives FDA Fast Track Designation for SGT …
Jan 21, 2025 · Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy ...
Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease caused by the absence of dystrophin, a membrane-stabilizing protein encoded by the DMD gene. Although mouse models of DMD provide insight into the potential of a corrective therapy, data from genetically homologous large animals, such as
Solid Biosciences, Charlestown, MA; 2. University of California at Los Angeles, Los Angeles, CA; 3. University of Florida, Gainesville, FL. Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease caused by mutations in the . DMD. gene that lead to the absence of functional dystrophin protein. Introduction / Objective. Duchenne ...
Solid Biosciences Added to the Nasdaq Biotechnology Index
Dec 23, 2024 · Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated ...
Investor Relations • Solid Biosciences Inc.
Jan 15, 2025 · Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy ...
Solid Biosciences Reports Inducement Grants Under Nasdaq …
Jan 6, 2025 · Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT ...
- Some results have been removed